Despite high tumor mutational burden (TMB) being often considered as a marker of responsive anti-PD1/PDL1 therapy, studies revealed that the resistance of PD1/PDL1 blockade in some high-mutated tumors was probably attributed to the JAK1/2 mutations. The gene discussed is PDCD1; the disease is neoplasm.